Highlights

  • Hydration Pharmaceuticals operates as Hydralyte USA, Marketing oral rehydration and wellness products to American consumers.
  • Loss after tax was USD 1.06 million, down 27%, and the EBITDA loss fell 31% to USD 1.23 million.
  • In June 2026 the company raised about AUD 392,000 through a Placement of 98 million shares at AUD 0.004 each.
  • Revenue depends partly on a small number of retail relationships, as the Publix decline showed.

The Hydration Pharmaceuticals Company Limited (ASX:HPC), which sells Hydralyte electrolyte products in the United States, is cutting costs while its auditor warns about its ability to keep operating. In its half-year report dated 31 August 2026, auditor RSM Australia Partners drew attention to a material uncertainty over going concern. The directors' own Cash Flow forecasts assume the company will raise more Capital or secure other funding within the next twelve months.

What the company does

Its products are sold online and through physical retailers. In recent years it has broadened the range with products in what it calls the better-for-you category, including gut health and liver support formulations. The company reports in US dollars.

Half-year results

Management attributed the decline mainly to lower ready-to-drink sales at US supermarket chain Publix and temporary out-of-stocks of two variety packs. Gross Profit fell to USD 414,945 from USD 753,209.

Losses narrowed, however. The report said the company paused its TikTok Investment during 2026.

June quarter and cost cuts

Online sales accounted for USD 517,908 of that total. Net operating cash outflow fell by around 45% to USD 334,000.

The company said it planned to reduce Advertising and marketing from about 42% of gross Revenue to about 32%, and to cut staff and contractor costs to around USD 110,000 in the following quarter. It targeted annual savings of about USD 360,000 from headcount reductions and outsourcing its finance function. These are company targets, not results.

Shares on issue rose to 537,988,485 by 30 June 2026. On 24 June, Joseph Constable and Adem Karafili resigned from the board, and George Karafotias and Nick Katiforis were appointed. The company also said it was undertaking a strategic review of capital management and Acquisition opportunities.

Share Trading on 16 November

The 50% gain shown for the day is equivalent to a single tick, from AUD 0.002 to AUD 0.003, at these very low prices.

Risks and what to watch

The Going Concern note is the central risk. With cash of under half a million US dollars at 30 June and continuing operating outflows, the company is likely to need fresh funding, and placements at sub-cent prices dilute existing holders heavily. The US hydration and wellness market is crowded with larger, better-funded brands.

That report, any outcome from the strategic review and any new capital raising are the key items to watch.